Aldehyde dehydrogenase inhibitors: α,β-Acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but irreversible apoptogens for cancer epithelial cells from human prostate in culture
摘要:
The pharmacomodulation of the N atom of alpha,beta-acetylenic aminothiolesters or the replacement of the thiolester moiety by more electroplfflic groups did not permit any clear rationale to be established for improving the selective growth-inhibitory activity of this family of compounds over that of the previously synthesized alpha,beta-acetylenic aminothiolesters DIMATE and MATE [G. Quash, G. Fournet, J. Chantepie, J. Gore, C. Ardiet, D. Ardail, Y. Michal, U. Reichert, Biochem Phannacol 64 (2002) 1279-92]. Hence DIMATE and MATE were investigated more thoroughly for selectivity and growth-inhibitory activity using human prostate epithelial normal cells (HPENC) on the one hand and human prostate epithelial cancer cells (DU145) on the other. Unequivocal evidence was obtained showing that both compounds were reversible growth inhibitors of HPENC but irreversible growth inhibitors of DU145. Growth-inhibition of DU145 was due to the induction of early apoptosis as revealed by the flow cytometric analytical profile of inhibitor-treated cells, of the decrease in the redox potential and increase in superoxide anion content of their mitochondria. Of the two intracellular enzymes: aldehyde dehydrogenases 1 and 3 (ALDH1 and ALDH3) targeted by DIMATE and MATE, ALDH3 was inhibited to the same extent by both compounds whereas ALDH1 was less susceptible to inhibition by MATE. As the induction of ALDH3 by xenobiotics is hormone-dependent, MATE, the more selective of the two inhibitors, is a useful tool not only for examining the role of the ALDH3 isoform in hormone-sensitive and resistant prostate cancer cells in culture but also for investigating if it can inhibit the growth of xenografts of prostate cancer in immunodeficient mice. (C) 2007 Elsevier Masson SAS. All rights reserved.
Heterobicyclic thiophene compounds and methods of use
申请人:Blake F. James
公开号:US20070197537A1
公开(公告)日:2007-08-23
Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
An anticancer agent comprising a compound represented by the formula (I) [R
1
represents hydrogen atom, hydroxyl group, a C
1-6
alkoxy group and the like; R
2
and R
3
represents hydrogen atom, a halogen atom, a C
1-6
alkyl group and the like; R
4
represents hydrogen atom, a C
1-6
alkyl group, a C
1-6
alkylsulfonyl group and the like; R
5
represents hydrogen atom or a substituent;
represents a single bond or a double bond; R
6
and R
7
represents hydrogen atom, a C
1-6
alkyl group and the like; R
8
represents hydrogen atom, a C
1-6
alkyl group and the like; A represents —O—, —S—, or —CH
2
—; D represents —C═ or —N═; X represents methylene group, —O—, or —CO—; Q represents —N═ or —C(R
8
)═; and Y represents a heterocyclic group or amino group], which shows a superior inhibitory activity against pim-1 kinase.
Propargylamines are effectively transformed to 2-dimethylphenylsilylmethyl-2-alkenals by the interaction of two equivalents of Me2PhSiH under silylformylation conditions catalyzed by Rh4(CO)12. The products are not obtained directly by silylformylation of the corresponding allenes.
Geri Roberto, Polizzi Carmela, Lardicci Luciano, Caporusso Anna Maria, Gazz. chim. ital, 124 (1994) N 6, S 241-248
作者:Geri Roberto, Polizzi Carmela, Lardicci Luciano, Caporusso Anna Maria
DOI:——
日期:——
HETEROBICYCLIC THIOPHENE COMPOUNDS FOR THE TREATMENT OF CANCER